Please Wait
Applying Filters...
menu
    • menu
    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-08-25

    Virtual Booth

    An Enquiry

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-08-25

    Virtual Booth

    An Enquiry

    Menu

    Stenoparib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Allarity Gets FDA Fast Track for Stenoparib in Ovarian Cancer
    Allarity Gets FDA Fast Track for Stenoparib in Ovarian Cancer

    26 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/26/3139198/0/en/Allarity-Therapeutics-Granted-FDA-Fast-Track-Designation-for-Stenoparib-for-the-Treatment-of-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    26 Aug 2025
    Share Share
    Allarity Therapeutics Doses Second Patient in Stenoparib Phase 2
    Allarity Therapeutics Doses Second Patient in Stenoparib Phase 2

    27 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/27/3106506/0/en/Allarity-Therapeutics-Announces-Dosing-of-Second-Patient-in-New-Phase-2-Trial-of-Stenoparib-in-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    27 Jun 2025
    Share Share
    Allarity Dose 1st Patient in Ph2 Stenoparib Ovarian Cancer Trial
    Allarity Dose 1st Patient in Ph2 Stenoparib Ovarian Cancer Trial

    05 Jun 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/diagnostic-center/allarity-announces-enrolment-of-first-patient-in-phase-2-clinical-trial-protocol-of-stenoparib-in-advanced-ovarian-cancer-17245

    INDPHARMAPOST
    05 Jun 2025
    Share Share
    Allarity Therapeutics Enrolls First Patient in Stenoparib Phase 2
    Allarity Therapeutics Enrolls First Patient in Stenoparib Phase 2

    02 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/02/3091778/0/en/Allarity-Therapeutics-Announces-First-Patient-Enrolled-in-New-Phase-2-Clinical-Trial-Protocol-of-Stenoparib-in-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    02 Jun 2025
    Share Share
    Allarity Therapeutics Q1 2025 Update: Stenoparib Benefit
    Allarity Therapeutics Q1 2025 Update: Stenoparib Benefit

    09 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/09/3078515/0/en/Allarity-Therapeutics-Provides-First-Quarter-2025-Update-Highlighting-Continued-Stenoparib-Benefit-and-Upcoming-Trial-Enrollment.html

    GLOBENEWSWIRE
    09 May 2025
    Share Share
    Allarity's Ph2 Stenoparib Lung Cancer Trial Fully Funded By VA
    Allarity's Ph2 Stenoparib Lung Cancer Trial Fully Funded By VA

    06 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/06/3038114/0/en/Allarity-Therapeutics-Announces-Phase-2-Trial-of-Stenoparib-in-Combination-with-Temozolomide-for-Recurrent-Small-Cell-Lung-Cancer-Fully-Funded-by-the-US-Veterans-Administration.html

    GLOBENEWSWIRE
    06 Mar 2025
    Share Share